These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39070357)

  • 1. Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Lipoprotein (a) and Other Biomarkers.
    Muñoz Rossi FA; Salazar Agudelo J; Quinapanta Castro NI; Mosquera SZ; Mejia Fajardo MC; Mosquera López ED; Espitia Olarte JD; Figueroa Medina MA; Zuniga Simancas E; Saldarriaga Osuna LF
    Cureus; 2024 Jun; 16(6):e63019. PubMed ID: 39070357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between neutrophil-to-high-density lipoprotein cholesterol ratio and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in the US population: a nationally representative cross-sectional study using NHANES data from 2017 to 2020.
    Lu Y; Xu X; Wu J; Ji L; Huang H; Chen M
    BMC Gastroenterol; 2024 Sep; 24(1):300. PubMed ID: 39237899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
    Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ
    Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
    ; ;
    Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.
    Marti-Aguado D; Calleja JL; Vilar-Gomez E; Iruzubieta P; Rodríguez-Duque JC; Del Barrio M; Puchades L; Rivera-Esteban J; Perelló C; Puente A; Gomez-Medina C; Escudero-García D; Serra MA; Bataller R; Crespo J; Arias-Loste MT
    J Hepatol; 2024 Jul; ():. PubMed ID: 38971533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
    Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
    World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study.
    Martínez-Montoro JI; Martínez-Sánchez MA; Balaguer-Román A; Fernández-Ruiz VE; Hernández-Barceló JE; Ferrer-Gómez M; Frutos MD; Núñez-Sánchez MÁ; Fernández-García JC; Ramos-Molina B
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
    Noureddin N; Copur-Dahi N; Loomba R
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.
    Salvoza N; Giraudi P; Gazzin S; Bonazza D; Palmisano S; de Manzini N; Zanconati F; Raseni A; Sirianni F; Tiribelli C; Rosso N
    J Transl Med; 2023 Dec; 21(1):906. PubMed ID: 38082368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease.
    Mak AL; Wassenaar N; van Dijk AM; Troelstra M; Houttu V; van Son K; Driessen S; Zwirs D; van den Berg-Faay S; Shumbayawonda E; Runge J; Doukas M; Verheij J; Beuers U; Nieuwdorp M; Cahen DL; Nederveen A; Gurney-Champion O; Holleboom A
    JHEP Rep; 2024 Mar; 6(3):100998. PubMed ID: 38379586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
    Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
    Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
    Con D; Tu S; Clayton-Chubb D; Lubel JS; Nicoll AJ; Sawhney R; Bloom S
    Dig Dis Sci; 2024 Apr; 69(4):1496-1506. PubMed ID: 38376788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis.'.
    Li C; Wang T; Song J
    Curr Probl Cardiol; 2024 Jul; 49(7):102626. PubMed ID: 38718937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Metabolic-Dysfunction-Associated Steatotic Liver Disease and Hepatic Cancer: Current Concepts and Future Challenges.
    Bader H; Yamin S; Alshahwan H; Farraj H; Maghnam J; Abu Omar Y
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892843
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.